0.460
-0.01 (-1.94%)
| Penutupan Terdahulu | 0.469 |
| Buka | 0.500 |
| Jumlah Dagangan | 433,017 |
| Purata Dagangan (3B) | 934,698 |
| Modal Pasaran | 24,282,334 |
| Harga / Jualan (P/S) | 29.53 |
| Harga / Buku (P/B) | 6.03 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Feb 2026 |
| EPS Cair (TTM) | -0.940 |
| Nisbah Semasa (MRQ) | 3.72 |
| Aliran Tunai Operasi (OCF TTM) | -16.75 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -10.69 M |
| Pulangan Atas Aset (ROA TTM) | -38.60% |
| Pulangan Atas Ekuiti (ROE TTM) | -555.68% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Iterum Therapeutics plc | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | -0.5 |
| Purata | 0.88 |
|
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 1.03% |
| % Dimiliki oleh Institusi | 6.41% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Apollon Financial, Llc | 30 Sep 2025 | 250,250 |
| Gen-Wealth Partners Inc | 30 Sep 2025 | 82,047 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 23 Dec 2025 | Pengumuman | Iterum Therapeutics Provides Business Update |
| 17 Dec 2025 | Pengumuman | Iterum Therapeutics Provides Business Update |
| 05 Dec 2025 | Pengumuman | Iterum Therapeutics Provides Business Update |
| 24 Nov 2025 | Pengumuman | Iterum Therapeutics Provides Business Update |
| 14 Nov 2025 | Pengumuman | Iterum Therapeutics Reports Third Quarter 2025 Financial Results |
| 07 Nov 2025 | Pengumuman | Iterum Therapeutics to Report Third Quarter 2025 Financial Results on Friday, November 14, 2025 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |